CDI Laboratories is the NextGen Proteomics™ company, a result of intensive efforts and advances made by synthetic biologists at the Johns Hopkins University School of Medicine.
The company was created by scientists for scientists to address critical needs required accelerate research, advance discoveries, and translate these discoveries into novel products and services that improve human health. Our flagship product, HuProt™ — the Human Proteome Microarray — has gone through several upgrades in content & print quality.
An archive of public press-releases announcing important events at CDI Laboratories.
APRIL 2017 – CDI LABORATORIES AND NEOBIOTECHNOLOGIES FORM ALLIANCE TO DISTRIBUTE CDI’S 2500 MONOSPECIFIC TRANSCRIPTION FACTOR ANTIBODIES
MAY 2017 – CDI LABS EXPANDS HUPROT™ – THE HIGHEST CONTENT HUMAN PROTEOME MICROARRAY IN THE WORLD
NOVEMBER 2017 – THE WORLD’S LARGEST HUMAN PROTEOME MICROARRAY: ADVANCING PROTEIN BIOMARKER DISCOVERY
NOVEMBER 2017 – CDI LABS CITES NEW RESEARCH IDENTIFYING EARLY LUNG CANCER AUTOANTIBODY BIOMARKERS USING HUPROT™
MARCH 2018 – CDI LABS COLLABORATES ON DISCOVERY OF NEW BIOMARKERS FOR ZIKA INFECTION
MARCH 2018 – CDI LABS’ MONOCLONAL ANTIBODY DEVELOPMENT PIPELINE FEATURED IN NATURE METHODS
APRIL 2018 – CDI LABORATORIES INC. OPENS $17M BIOTECH LAB IN MAYAGÜEZ
MARCH 2019 – CDI LABS RELEASES HUPROT™ V4.0 – ADDING ADDITIONAL CONTENT TO LARGEST CONTENT HUMAN PROTEOME MICROARRAY IN THE WORLD
MARCH 2019 – CDI LABS TO SHOWCASE IMMUNO-ONCOLOGY PRODUCTS & SERVICES AT AACR 2019
FEBRUARY 2020 – CDI LABS LAUNCHES TWO NEW POWERFUL ASSAYS TO ITS BIOMARKER DISCOVERY PLATFORM
SEPTEMBER 2020 – CDI LABS HUPROT™ PROTEIN ARRAYS INSTRUMENTAL IN RECENT STUDY OF MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN (MIS-C)
JANUARY 2023 – BROADOAK CAPITAL PARTNERS INVESTS IN CDI LABORATORIES TO EXPAND AND SCALE ANTIBODY BIOMARKER DISCOVERY PLATFORMS